Showing results (1311-1320 of 4,882) with videos related to
Sort By:
Pageof 489
Urologic Oncology|October 26, 2019
Immunohistochemical negative expression of ezrin predicts poor prognosis in clear cell renal cell carcinomaMarcos Vinicius O Ferrari, Walter Henriques da Costa, Mariana Andozia Morini Matushita, et al.Urologic Oncology|October 27, 2019
The role of salvage lymph node dissection in nonmetastatic castration-resistant prostate cancer: A single center experienceLuca Boeri, Vidit Sharma, Avinash Nehra, et al.Urologic Oncology|October 27, 2019
Impact of timing on salvage radiation therapy adverse events following radical prostatectomy: A secondary analysis of the RTOG 9601 cohortLee Baumgarten, Alex Borchert, Akshay Sood, et al.Urologic Oncology|August 14, 2016
Krüppel-like factor 4 is a novel prognostic predictor for urothelial carcinoma of bladder and it regulates TWIST1-mediated epithelial-mesenchymal transitionWei-Cheng Tseng, Cheng-Wei Chuang, Muh-Hwa Yang, et al.Urologic Oncology|August 6, 2021
Cancer-specific outcomes for prostate cancer patients who had prebiopsy prostate MRIJonathan Li, Dattatraya Patil, Martin G Sanda, et al.Urologic Oncology|May 23, 2021
Serum testosterone levels and testosterone 'bounce' phenomenon predict response to novel anti-androgen therapies in castration-resistant prostate cancerYu Guang Tan, Sheriff Z H Quek, Hong Hong Huang, et al.Urologic Oncology|May 23, 2021
Leibovich score is the optimal clinico-pathological system associated with recurrence of non-metastatic clear cell renal cell carcinomaJames P Blackmur, Fortis Gaba, Dilini Fernando, et al.Urologic Oncology|June 15, 2020
Oncologic outcomes of laparoscopic radical nephroureterectomy in conjunction with template-based lymph node dissection: An extended follow-up studyRyuji Matsumoto, Takashige Abe, Norikata Takada, et al.Urologic Oncology|December 22, 2004
Cisplatin inhibits the expression of X-linked inhibitor of apoptosis protein in human LNCaP cellsTakeo Nomura, Hiromitsu Mimata, Mutsushi Yamasaki, et al.Urologic Oncology|December 22, 2004
Why a statin and/or another proven heart healthy agent should be utilized in the next major cancer chemoprevention trial: part IMark A MoyadPageof 489